Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S38, October 2017

Beneficial Impact of Direct Oral Anticoagulants on Mortality in Patients with Heart Failure and Atrial Fibrillation

      Background: It has been reported that direct oral anticoagulants (DOAC) reduce cardiovascular event in patients with atrial fibrillation (AF). We examined impacts of DOAC on mortality in heart failure (HF) patients with AF. Methods and Results: Consecutive 352 hospitalized HF patients with AF were divided into 3 groups: non-anticoagulant group (n = 67), Vit K antagonist (VKA) group (n = 210) and DOAC group (n = 75). In Kaplan-Meier analysis, all-cause mortality was significantly higher in non-anticoagulant group than in VKA and DOAC groups (P < .01). In multivariable analysis, the use of DOAC, but not VKA, was an independent predictor of mortality in HF patients with AF (DOAC, HR 0.432, P = .038; VKA, HR 0.626, P = .070). Conclusion: Appropriate use of anticoagulants in HF patients with AF is important, and DOAC may improve mortality in HF patients with AF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect